Comparing Two Ways of Continuing Secukinumab Treatment in People With Psoriasis
Looks back at two secukinumab maintenance patterns and long-term results in psoriasis.
Plain-language title generated from the registry record
Registry title: Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis
Key facts
- Where
- Nanjing, ChinaSee the site
Where in China
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medicine SchoolNanjing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Trial code
- NCT07642544
- Record updated
- 11 June 2026
- Original description
To evaluate the long-term efficacy of two maintenance treatment patterns of secukinumab-the standard maintenance group and the non-standard maintenance group-by assessing the median time to onset and incidence of secondary failure, as well as the time to regain response after dose escalation of secukinumab (including re-initiation of intensive dosing or shortening of the injection interval) in patients who experienced secondary failure.Read full original descriptionShow less
Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis: A Single-Center Real-World Cross-Sectional Retrospective Study
To evaluate the long-term efficacy of two maintenance treatment patterns of secukinumab-the standard maintenance group and the non-standard maintenance group-by assessing the median time to onset and incidence of secondary failure, as well as the time to regain response after dose escalation of secukinumab (including re-initiation of intensive dosing or shortening of the injection interval) in patients who experienced secondary failure.
Inclusion: Age ≥ 18 years, with a clinical diagnosis of moderate-to-severe plaque psoriasis; Initiated secukinumab treatment at our center between January 2020 and December 2025, and completed the standard 5-week induction period; Achieved PASI 75 response at the end of the induction period; Had a clearly defined maintenance treatment pattern (standard or non-standard), with complete treatment records and regular efficacy assessments; Complete electronic medical record data available for extraction.
Exclusion: Use of other targeted biologic agents or small molecule drugs during the maintenance period; Failure to complete the induction period, or failure to achieve PASI 75 response by the end of the induction period; Permanent discontinuation of treatment for non-efficacy reasons, such as pregnancy, severe infection, or malignancy; Irregular maintenance treatment pattern, or substantial missing data; Participation in other interventional clinical trials that may confound efficacy assessment.